NASDAQ · Health care

PDS Biotechnology Corp (PDSB)

It posted a net loss of $33.7M. In fiscal 2025 capital spending exceeded operating cash flow by $27.8M. At June 30, 2026 it held $5.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch PDSB in 60 seconds

Price

$1.02

-0.97% on the day · November 11, 2026

52-week range $0.20 to $1.79

Market cap

$57.1M

Key facts about PDS Biotechnology Corp

Net worth: PDS Biotechnology Corp has a market value (market cap) of $57.1M at the latest share price, and shareholders' equity of -$3.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Cash flow: In fiscal 2025 operations used $27.8M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report: PDS Biotechnology Corp's next report was expected around October 20, 2026 and is not on file with the SEC yet.

What PDS Biotechnology Corp does

PDS Biotechnology Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PDSB.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$31.5M	-$34.5M	-$0.74	-$27.8M
2024	n/a	-$36.3M	-$37.6M	-$1.03	-$35.1M
2023	n/a	-$43M	-$42.9M	-$1.39	-$33.6M
2022	n/a	-$41.7M	-$40.9M	-$1.43	n/a
2021	n/a	-$21.4M	-$16.9M	-$0.66	n/a
2020	n/a	-$14.9M	-$14.8M	-$0.89	n/a

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

A report was expected around October 20, 2026 and is not on file yet.

Estimated from its filing rhythm: about 68 days after its last report of August 13, 2026, its usual gap. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Latest SEC filings

What PDS Biotechnology Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

October 6, 2026
Other event 8-K
September 22, 2026
Other event 8-K
September 21, 2026
Activist stake (5% or more) SCHEDULE 13D
September 21, 2026
Other event 8-K
September 14, 2026
Executive or director change 8-K
September 8, 2026
Material agreement 8-K
September 4, 2026
Material agreement 8-K
August 25, 2026
Executive or director change 8-K
August 19, 2026
Executive or director change 8-K
August 14, 2026
Bylaws or fiscal year changed 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 21, 2026. Insider transactions on SEC

Insider trades

What the people running PDS Biotechnology Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PDSB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Nant Capital, LLC13D, may seek influence with 1 related filers	19.9%	20,336,335	September 21, 2026

Latest filings below 5%: Armistice Capital, LLC 4.99% (August 14, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PDSB

What does PDS Biotechnology Corp do?

PDS Biotechnology Corp is a company in the Health care sector, listed on NASDAQ as PDSB. Its shares trade on NASDAQ under the ticker PDSB.

What is PDS Biotechnology Corp's net worth?

PDS Biotechnology Corp has a market value (market cap) of $57.1M at the latest share price, and shareholders' equity of -$3.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is PDS Biotechnology Corp profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $33.7M.

When did PDS Biotechnology Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 6, 2026.

When is PDS Biotechnology Corp's next earnings report?

PDS Biotechnology Corp's next report was expected around October 20, 2026 and is not on file with the SEC yet.

Similar companies

Heron Therapeutics, Inc.

RNAZ

Transcode Therapeutics, Inc.

Compare PDSB with

Compare PDSB with any company

Follow PDSB

Get an email when PDS Biotechnology Corp files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values PDS Biotechnology Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.